Kidney Cancer

Utilization Patterns Explain Nonadherence to Treatment for Multiple Myeloma, CML, Some Metastatic Cancers

Publish Date October 22, 2021

A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.

Sex Inequalities Persist in Cancer Clinical Trials

Publish Date October 7, 2021

Men nearly always outnumbered women, regardless of trial phase, cancer type, time period, or cancer incidence in the female population.

Most Solid Tumor Patients Have ‘Adequate’ Response to COVID-19 Vaccination, Regardless of Treatment

Publish Date October 4, 2021

Responses in cancer patients were noninferior to responses in patients without cancer.

Preoperative Blood Glucose Level Linked to Length of Stay After Nephrectomy for Renal Cell Carcinoma

Publish Date September 22, 2021

Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.

First-Line Advanced RCC Combo Tx Improves Outcomes Regardless of Prior Surgery

Publish Date September 17, 2021

As first-line therapy for advanced renal cell carcinoma, nivolumab plus cabozantinib prolongs progression-free survival compared with sunitinib in patients with and without a prior nephrectomy.

RCC Subtype Affects Post-Nephrectomy Survival Rates

Publish Date September 13, 2021

Five-year survival rates following nephrectomy for renal cell carcinoma are higher among patients with favorable vs unfavorable histology.

Lower Post-Nephrectomy Kidney Function May Up ESKD Risk

Publish Date September 12, 2021

New study findings “are critically important in patient counseling and surgical planning, particularly for patients with risk factors for renal deterioration,” according to investigators.

Study: Chest Imaging After RCC Surgery Not Warranted

Publish Date September 11, 2021

Investigators concluded that there is minimal to no clinical value in surveillance for pulmonary recurrence after T1a RCC resection.

Welireg Approved for Cancers Associated With Von Hippel-Lindau Disease

Publish Date August 17, 2021

The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other VHL-associated tumors.

Pembrolizumab Plus Axitinib Best Improves Overall and Progression-Free Survival in Metastatic Renal Cell Carcinoma

Publish Date August 16, 2021

Researchers concluded that pembrolizumab plus axitinib may be the most effective first-line immunotherapy for mRCC